{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:27:18Z","timestamp":1787506038252,"version":"build-2736575974"},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Despite recent advances in first\u2010line therapies for multiple myeloma (MM), most patients relapse or become refractory, underscoring the need for effective second\u2010line (2L) regimens for relapsed\/refractory MM (RRMM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study describes the real\u2010world baseline characteristics, treatment patterns and clinical outcomes of adult patients diagnosed with MM between 2013 and 2020 using data collated by the National Cancer Registration and Analysis Service (NCRAS) of the National Health Service in England. The study cohorts were broadly aligned to the eligibility criteria of the ongoing DREAMM\u20107 (D7) and DREAMM\u20108 (D8) clinical trials. We focus on lenalidomide\u2010exposed\/refractory patients who received daratumumab\u2013bortezomib\u2013dexamethasone (DaraVd) at 2L in both cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the D7\u2010like cohort, the lenalidomide\u2010exposed (\n                      <jats:italic>n\u00a0<\/jats:italic>\n                      =\u00a0282) and lenalidomide\u2010refractory (\n                      <jats:italic>n\u00a0<\/jats:italic>\n                      =\u00a0143) patients who received DaraVd at 2L had a median (95% confidence interval [CI]) time to next treatment or death (TTNTD) of 15.1 (12.6\u201322.4) and 10.3 (7.4\u201313.9) months, respectively. In the D8\u2010like cohort, the lenalidomide\u2010exposed (\n                      <jats:italic>n\u00a0<\/jats:italic>\n                      =\u00a0269) and lenalidomide\u2010refractory (\n                      <jats:italic>n\u00a0<\/jats:italic>\n                      =\u00a0148) patients who received DaraVd at 2L had a median (95% CI) TTNTD of 14.5 (11.7\u201319.7) and 10.0 (7.3\u201313.7) months, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with RRMM in England receiving DaraVd at 2L have poor clinical outcomes, highlighting the urgent need for new therapies, particularly for lenalidomide\u2010refractory patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jha2.1058","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T14:49:23Z","timestamp":1733410163000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real\u2010world characteristics and outcomes of patients with multiple myeloma receiving second\u2010line treatment in England"],"prefix":"10.1002","volume":"6","author":[{"given":"Sally","family":"Moore","sequence":"first","affiliation":[{"name":"Department of Haematology University Hospitals Bristol and Weston NHS Foundation Trust  Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cornic","sequence":"additional","affiliation":[{"name":"GSK  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina\u2010Jane","family":"Crossman\u2010Barnes","sequence":"additional","affiliation":[{"name":"GSK  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Jose","sequence":"additional","affiliation":[{"name":"Health Data Insight CIC  Cambridge UK"},{"name":"National Disease Registration Service NHS England  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyad","family":"Khalaf","sequence":"additional","affiliation":[{"name":"GSK  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwee","family":"Yong","sequence":"additional","affiliation":[{"name":"Department of Haematology University College Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Soutar","sequence":"additional","affiliation":[{"name":"GSK  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7174-8115","authenticated-orcid":false,"given":"Philip","family":"Woods","sequence":"additional","affiliation":[{"name":"GSK  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"e_1_2_13_3_1","unstructured":"Cancer Research UK.Myeloma statistics. Available from:https:\/\/www.cancerresearchuk.org\/health\u2010professional\/cancer\u2010statistics\/statistics\u2010by\u2010cancer\u2010type\/myeloma\/survival2018#:~:text=There%20are%20around%206%2C000%20new year%20(2016%2D2018). Accessed 19 Feb 2024."},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01109-y"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14213"},{"key":"e_1_2_13_6_1","volume-title":"Myeloma: diagnosis and management","author":"National Institute of Health and Care Excellence","year":"2018"},{"key":"e_1_2_13_7_1","volume-title":"Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma [TA680]","author":"National Institute of Health and Care Excellence","year":"2021"},{"key":"e_1_2_13_8_1","volume-title":"Bortezomib for induction therapy in multiple myeloma before high\u2010dose chemotherapy and autologous stem cell transplantation [TA311]","author":"National Institute for Health and Care Excellence","year":"2014"},{"key":"e_1_2_13_9_1","volume-title":"Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable","year":"2022"},{"key":"e_1_2_13_10_1","volume-title":"Bortezomib and thalidomide for the first\u2010line treatment of multiple myeloma [TA228]","year":"2011"},{"key":"e_1_2_13_11_1","volume-title":"Lenalidomide plus dexamethasone for previously untreated multiple myeloma [TA587]","author":"National Institute for Health and Care Excellence","year":"2019"},{"key":"e_1_2_13_12_1","volume-title":"Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [TA917]","author":"National Institute of Health and Care Excellence","year":"2023"},{"key":"e_1_2_13_13_1","volume-title":"Bortezomib monotherapy for relapsed multiple myeloma [TA129]","author":"National Institute for Health and Care Excellence","year":"2007"},{"key":"e_1_2_13_14_1","volume-title":"Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma [TA695","author":"National Institute for Health and Care Excellence","year":"2021"},{"key":"e_1_2_13_15_1","volume-title":"Carfilzomib for previously treated multiple myeloma [TA657]","author":"National Institute for Health and Care Excellence","year":"2020"},{"key":"e_1_2_13_16_1","volume-title":"Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib [TA586]","author":"National Institute of Health and Care Excellence","year":"2019"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32292-3"},{"key":"e_1_2_13_18_1","volume-title":"Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma [TA974]","author":"National Institute for Health and Care Excellence","year":"2024"},{"key":"e_1_2_13_19_1","volume-title":"Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma [TA897]","author":"National Institute of Health and Care Excellence","year":"2019"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405090"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403407"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.623"},{"key":"e_1_2_13_23_1","doi-asserted-by":"crossref","unstructured":"Maria\u2010Victoria MateosPR HusM FuC ZherebtsovaV WardC Joy HoP et\u00a0al.DREAMM\u20107 update: subgroup analyses from a phase 3 trial of belantamab mafodotin (belamaf) + bortezomib and dexamethasone (BVd) vs daratumumab bortezomib and dexamethasone (DVd) in relapsed\/refractory multiple myeloma (RRMM).2024. Available from:https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2024.42.16_suppl.7503. Accessed 7 Mar 2024.","DOI":"10.1016\/S2152-2650(24)01705-1"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18703"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0422"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04312-9"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.06.007"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051558"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.1058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T02:33:36Z","timestamp":1741746816000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.1058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1002\/jha2.1058"],"URL":"https:\/\/doi.org\/10.1002\/jha2.1058","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"assertion":[{"value":"2024-10-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1058"}}